How effective is targeted therapy for non-small cell lung cancer?

Non-small cell lung cancer includes several tumour types. Treatment selection commonly depends on molecular testing of tumour tissue or another approved sample. A driver change can make a tumour more likely to respond to a matching medicine, but it does not predict the exact result for one person. Doctors use scans, breathing symptoms, pain, weight, examination and blood tests to judge benefit. If cancer later grows, a repeat sample or additional testing may identify resistance and guide the next choice.

Ask whether your tumour has been tested for the changes relevant to treatment and whether the sample was adequate. Clarify how and when response will be reviewed, which medicines or supplements may interfere, and what to do after a missed dose. Report new cough, breathlessness, diarrhoea, rash, swelling, vision changes or severe fatigue. Keep appointments even when symptoms improve, because treatment decisions rely on both how you feel and what imaging shows.

Seek urgent advice for new or rapidly worsening breathlessness, chest pain, coughing blood, severe diarrhoea, inability to keep fluids down, facial swelling or a widespread blistering rash. Emergency care is appropriate for severe breathing difficulty, fainting, confusion or sudden weakness. Do not wait for the next scan when these symptoms appear.

What driver change was found, if any? Is the treatment intended to shrink disease, control it or relieve symptoms? What scan findings would lead to a change? How will lung inflammation or other side effects be checked? What is the plan if resistance develops?